A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis.
Rhinitis is a very common disease and represents a health problem for both children and adults globally. Rhinitis can be allergic or occur without any IgE-mediated sensitization to aeroallergens. Common symptoms include nasal congestion, postnasal drainage, nasal itching, rhinorrhea and sneezing. The most effective drugs for the treatment of rhinitis are antihistamines and topical glucocorticoids. MP29-02 (Dymista(®)) is a novel intranasal formulation combining the second-generation antihistamine, azelastine hydrochloride, with fluticasone propionate in a single device that has recently been developed. Here, we review the efficacy and safety profile of this intranasal formulation in the treatment of allergic and nonallergic rhinitis.
Department of Clinical & Experimental Medicine, University of Parma, Parma, Italy.
Erminia
E
Ridolo
Department of Clinical & Experimental Medicine, University of Parma, Parma, Italy.
Marcello
M
Montagni
Department of Clinical & Experimental Medicine, University of Parma, Parma, Italy.
Valerie
V
Melli
Department of Clinical & Experimental Medicine, University of Parma, Parma, Italy.
Laura
L
Bonzano
Pulmonary Rehabilitation Unit, ICP Hospital, Milan, Italy.
Cristoforo
C
Incorvaia
Allergy & Respiratory Diseases Clinic, DIMI, University of Genoa, IRCCS AOU San Martino-IST, Genoa, Italy.
Giorgio Walter
GW
Canonica
D000281:Administration, Intranasal; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004338:Drug Combinations; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D010793:Phthalazines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
D000305:Adrenal Cortex Hormones; D000730:Androstadienes; D004338:Drug Combinations; D039563:Histamine H1 Antagonists, Non-Sedating; C573864:MP29-02; D010793:Phthalazines